Von der seltenen Nebenwirkung zur ernst zu nehmenden Erkrankung

Medikamenten-assoziierte Kiefernekrosen

Durch Prothesendruckstellen provozierte Medikamenten-assoziierte Kiefernekrose im Unterkiefer beidseits. MKG Heidelberg

 

Literaturliste

Bedogni, A., S. Fedele, et al. (2014). "Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease." Br J Oral Maxillofac Surg.

Bedogni, A., G. Saia, et al. (2011). "Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis." Oral Oncol 47(5): 420-424.

de-Freitas, N. R., L. B. Lima, et al. (2016). "Bisphosphonate treatment and dental implants: A systematic review." Medicina Oral Patología Oral y Cirugia Bucal: 0.

Dearnaley, D. P., M. D. Mason, et al. (2009). "Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials." Lancet Oncol 10(9): 872-876.

El-Rabbany, M., A. Sgro, et al. (2017). "Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis." J Am Dent Assoc 148(8): 584-594 e582.

Fedele, S., G. Bedogni, et al. (2015). "Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed." Br J Oral Maxillofac Surg 53(1): 13-17.

Fliefel, R., M. Troltzsch, et al. (2015). "Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review." Int J Oral Maxillofac Surg 44(5): 568-585.

Giovannacci, I., M. Meleti, et al. (2016). "Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?" The Journal of craniofacial surgery 27(3): 697–701.

Goodday, R. H. (2015). "Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw." Oral Maxillofac Surg Clin North Am 27(4): 527-536.

Grötz, K., J.-U. Piesold, et al. (2012). Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF online (www.awmf.org).

Grötz, K. and B. Al-Nawas (2016). "Antiresorptiva-assoziierte Kiefernekrose." MKG-Chirurg(9): 207–217.

Guggenberger, R., D. R. Fischer, et al. (2013). "Bisphosphonate-induced osteonecrosis of the jaw: comparison of disease extent on contrast-enhanced MR imaging, [18F] fluoride PET/CT, and conebeam CT imaging." AJNR Am J Neuroradiol 34(6): 1242-1247.

Hallmer, F., T. Bjornland, et al. (2014). "Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden." Oral Surg Oral Med Oral Pathol Oral Radiol 118(2): 202-208.

Hansen, T., M. Kunkel, et al. (2006). "Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis." J Oral Pathol Med 35(3): 155-160.

Hasegawa, T., A. Kawakita, et al. (2017). "A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?" Osteoporos Int.

Hasegawa, Y., M. Kawabe, et al. (2012). "Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related osteonecrosis of the jaws: A retrospective study." Oral surgery, oral medicine, oral pathology and oral radiology 114(3): 318–324.

Hoefert, S. and H. Eufinger (2011). "Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw." J Oral Maxillofac Surg 69(2): 362-380.

Hoff, A. O., B. B. Toth, et al. (2008). "Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates." J Bone Miner Res 23(6): 826-836.

Khan, A. A., A. Morrison, et al. (2015). "Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus." J Bone Miner Res 30(1): 3-23.

Kyrgidis, A., S. Triaridis, et al. (2012). "Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires." Anticancer Res 32(8): 3527-3534.

Lo, J. C., F. S. O'Ryan, et al. (2010). "Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure." J Oral Maxillofac Surg 68(2): 243-253.

Marx, R. E. (2003). "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic." J Oral Maxillofac Surg 61(9): 1115-1117.

Matsumoto, A., M. Sasaki, et al. (2017). "Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab." Clin Oral Investig 21(1): 127-134.

Montefusco, V., et al., Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma, 2008. 49(11): p. 2156-62.

Mozzati, M., V. Arata, et al. (2013). "Tooth extraction in osteoporotic patients taking oral bisphosphonates." Osteoporos Int 24(5): 1707-1712.

Nicolatou-Galitis, O., E. Papadopoulou, et al. (2011). "Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center." Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(2): 195-202.

Nicolatou-Galitis, O., E. Razis, et al. (2015). "Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review." Oral surgery, oral medicine, oral pathology and oral radiology 120(6): 699–706.

Niibe, K., T. Ouchi, et al. (2015). "Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab." Journal of prosthodontic research 59(1): 3–5.

Otto, S., S. Hafner, et al. (2009). "The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw." J Oral Maxillofac Surg 67(3): 589-592.

Otto, S., C. Pautke, et al. (2010). "Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism." J Oral Maxillofac Surg 68(11): 2837-2845.

Otto, S., C. Pautke, et al. (2018). "Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases." Cancer Treat Rev 69: 177-187.

Otto, S., O. Ristow, et al. (2016). "Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study." J Craniomaxillofac Surg 44(8): 1073-1080.

Otto, S., M. Troltzsch, et al. (2015). "Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?" J Craniomaxillofac Surg 43(6): 847-854.

Panya, S., R. Fliefel, et al. (2017). "Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)." J Craniomaxillofac Surg 45(3): 357-363.

Papapoulos, S., K. Lippuner, et al. (2015). "The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study." Osteoporos Int 26(12): 2773-2783.

Poxleitner, P., M. Engelhardt, et al. (2017). "The Prevention of Medication-related Osteonecrosis of the Jaw." Dtsch Arztebl Int 114(5): 63-69.

Raje, N., E. Terpos, et al. (2018). "Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study." Lancet Oncol 19(3): 370-381.

Rao, N. J., J. Y. Wang, et al. (2017). "Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws." BioMed research international 2017: 1560175.

Ripamonti, C. I., M. Maniezzo, et al. (2009). "Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan." Ann Oncol 20(1): 137-145.

Ristow, O., C. Gerngroß, et al. (2013). "Is the bone turnover of the jawbone and its possible oversuppression by bisphosphonates of etiological importance for the pathogenesis of the bisphosphonate-related osteonecrosis?" Journal of Oral and Maxillofacial Surgery.

Ristow, O., C. Gerngross, et al. (2014). "Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?" J Cancer Res Clin Oncol 140(3): 487-493.

Ristow, O., S. Otto, et al. (2017). "Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study." Int J Oral Maxillofac Surg 46(2): 157-166.

Ristow, O., S. Otto, et al. (2015). "Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)." J Craniomaxillofac Surg 43(2): 290-293.

Ristow, O., T. Ruckschloss, et al. (2018). "Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw - A single center cohort study." J Craniomaxillofac Surg 46(5): 815-824.

Rugani, P., G. Luschin, et al. (2014). "Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer." Clin Oral Investig 18(2): 401-407.

Ruggiero, S. L., T. B. Dodson, et al. (2014). "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update." J Oral Maxillofac Surg.

Ruggiero, S. L. and N. Kohn (2015). "Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw." J Oral Maxillofac Surg 73(12 Suppl): S94-S100.

Rupel, K., G. Ottaviani, et al. (2014). "A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)." Oral Oncol 50(11): 1049-1057.

Saad, F., J. E. Brown, et al. (2012). "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases." Ann Oncol 23(5): 1341-1347.

Saia, G., S. Blandamura, et al. (2010). "Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction." J Oral Maxillofac Surg 68(4): 797-804.

Schiodt, M., S. Vadhan-Raj, et al. (2018). "A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer." Support Care Cancer 26(6): 1905-1915.

Sedghizadeh, P. P., S. K. Kumar, et al. (2008). "Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy." J Oral Maxillofac Surg 66(4): 767-775.

Sivolella, S., F. Lumachi, et al. (2013). "Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease." Anticancer Res 33(5): 1793-1797.

Smith, M. R., F. Saad, et al. (2013). "Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time." J Clin Oncol 31(30): 3800-3806.

Sonis, S. T., L. S. Elting, et al. (2004). "Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients." Cancer 100(9 Suppl): 1995-2025.

Soundia, A., D. Hadaya, et al. (2018). "Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws." Oral Surg Oral Med Oral Pathol Oral Radiol.

Stopeck, A. T., K. Fizazi, et al. (2016). "Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer." Support Care Cancer 24(1): 447-455.

Thumbigere-Math, V., B. S. Michalowicz, et al. (2014). "Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw." Journal of periodontology 85(2): 226–233.

Troeltzsch, M., D. Cagna, et al. (2016). "Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis?" Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 44(12): 1945–1951.

Voss, P. J., G. Vargas Soto, et al. (2016). "Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla." Head Face Med 12: 3.

Wagner-Johnston, N. D., J. A. Sloan, et al. (2015). "5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial." Cancer 121(15): 2537-2543.

Walter, C., B. Al-Nawas, et al. (2010). "Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients." Head Face Med 6(1): 11.

Walter, C., B. Al-Nawas, et al. (2016). "Dental implants in patients treated with antiresorptive medication - a systematic literature review." Int J Implant Dent 2(1): 9.

Wazzan, T., D. Kashtwari, et al. (2018). "Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study." Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

Yoneda, T., H. Hagino, et al. (2017). "Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw." J Bone Miner Metab 35(1): 6-19.

27071952705928270592927059302706383 2699378 2705932
preload image 1preload image 2preload image 3preload image 4preload image 5preload image 6preload image 7preload image 8preload image 9preload image 10preload image 11preload image 12preload image 13preload image 14preload image 15preload image 16preload image 17preload image 18preload image 19preload image 20preload image 21preload image 22preload image 23preload image 24preload image 25preload image 26preload image 27preload image 28preload image 29preload image 30preload image 31preload image 32preload image 33preload image 34preload image 35preload image 36preload image 37preload image 38preload image 39preload image 40preload image 41preload image 42preload image 43preload image 44preload image 45preload image 46preload image 47preload image 48preload image 49preload image 50preload image 51preload image 52preload image 53preload image 54preload image 55preload image 56preload image 57preload image 58preload image 59preload image 60preload image 61preload image 62preload Themeimage 0preload Themeimage 1preload Themeimage 2preload Themeimage 3preload Themeimage 4preload Themeimage 5preload Themeimage 6preload Themeimage 7preload Themeimage 8preload Themeimage 9preload Themeimage 10preload Themeimage 11preload Themeimage 12preload Themeimage 13preload Themeimage 14preload Themeimage 15preload Themeimage 16preload Themeimage 17preload Themeimage 18preload Themeimage 19preload Themeimage 20preload Themeimage 21preload Themeimage 22preload Themeimage 23preload Themeimage 24preload Themeimage 25preload Themeimage 26preload Themeimage 27preload Themeimage 28
Bitte bestätigen Sie
Nein
Ja
Information
Ok
loginform
Kommentarvorschau
Kommentarvorschau schliessen
Antwort abbrechen
Ihr Kommentar ist eine Antwort auf den folgenden Kommentar

Keine Kommentare